Rapport Therapeutics Hits New 52-Week High of $52.81, Marking Major Milestone

Rapport Therapeutics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 52.81 on August 26, 2026. This achievement marks a notable increase from its 52-week low of USD 14.11, showcasing a substantial upward trend in the stock's performance over the past year. The company's market capitalization stands at USD 1,331 million, reflecting its position within the small-cap segment. Despite being a loss-making entity, Rapport Therapeutics has demonstrated resilience, with a one-year performance that outpaces the S&P 500 by 18.71%. Key financial metrics indicate a price-to-book ratio of 2.75, while the company currently does not offer a dividend yield. The debt-to-equity ratio is reported at -1.01, highlighting a unique financial structure. As Rapport Therapeutics continues to navigate the competitive landscape of the pharmaceuticals and biotechnology industry, its recent performance underscores a pivotal moment in its operational journey.